Brookstone Capital Management Grows Stock Holdings in Becton, Dickinson and Company $BDX

Brookstone Capital Management boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.2% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 19,500 shares of the medical instruments supplier’s stock after purchasing an additional 1,650 shares during the quarter. Brookstone Capital Management’s holdings in Becton, Dickinson and Company were worth $3,359,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Saudi Central Bank bought a new position in Becton, Dickinson and Company during the first quarter valued at $26,000. Smallwood Wealth Investment Management LLC bought a new position in shares of Becton, Dickinson and Company in the first quarter worth about $27,000. Alpine Bank Wealth Management bought a new position in shares of Becton, Dickinson and Company in the first quarter worth about $29,000. Cornerstone Planning Group LLC lifted its stake in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new stake in Becton, Dickinson and Company in the first quarter worth about $31,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on BDX. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Wells Fargo & Company upped their price objective on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. Three analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus price target of $205.40.

Becton, Dickinson and Company Stock Performance

BDX stock opened at $186.62 on Friday. The firm has a market cap of $53.49 billion, a price-to-earnings ratio of 33.56, a PEG ratio of 1.47 and a beta of 0.25. The firm has a 50-day simple moving average of $190.13 and a two-hundred day simple moving average of $184.19. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 1,838 shares of company stock worth $348,392 over the last ninety days. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.